Exchange: NASDAQ·Updated 01:34 PM EDT

BRVE Braveheart Bio Inc.

$28.25
$0.49
(1.76%)
Today
Mkt Cap$2.12B
Vol53,201.00

About BRVE

Braveheart Bio, Inc. engages in the development of therapeutics to treat hypertrophic cardiomyopathy. Its lead product candidate is BHB-1839 which is a small-molecule cardiac myosin inhibitor. The company was founded on May 13,2024 and is headquartered in San Francisco, CA.
40

Bearish Sentiment

How do you feel about BRVE?

Advertisement|Remove ads.